Empagliflozin
Physiological Effects of Drugs
National Institute on Aging (NIA)Small moleculePhase 4 / ApprovedDormant
BBB
73/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 59/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Physiological Effects of Drugs cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Vts-K Theresa Jacob, PhD, MPH | Phase 4 | BB |
Guanfacine Maimonides Medical Center | Phase 4 | BB |
Pioglitazone Yonsei University | Phase 4 | BB |
Dimethyloxobuthylphosphonilmethylate Tatchempharmpreparaty, JSC | Phase 3 | B |
PREDNISONE TABLETS Eli Lilly and Company | Phase 3 | B |
View all 17 →
Same molecule, other indications
Empagliflozin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →